Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SGN-75 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | SGN-75 |
| Name | Type | Description |
|---|---|---|
| SGN-75 | DRUG | SGN-75 (IV) in 21- or 28-day cycles; dose range: 0.3-9 mg/kg |
Inclusion Criteria: * Pathologically-confirmed diagnosis of NHL or RCC * Relapsed, refractory, or progressive disease following at least 1 prior systemic therapy * Confirmed CD70 expression * Measurable disease, defined as at least 1 lesion \>1.5 cm in the greatest transverse diameter for patients ...
SGN-75 is an investigational small molecule being studied for the treatment of renal cell carcinoma and CD70-positive non-Hodgkin lymphoma. It is in Phase 1 clinical development and is not yet approved by the FDA.
SGN-75 is being developed by Pfizer, Inc., which trades under the ticker symbol PFE. The drug is currently in Phase 1 clinical trials.
SGN-75 is in Phase 1 clinical development. It has completed one Phase 1 trial and is not yet approved by the FDA.
SGN-75 has one completed clinical trial, NCT01015911, which was a Phase 1 dose-escalation study in CD70-positive non-Hodgkin lymphoma or renal cell carcinoma. The trial enrolled 58 participants in the United States.
SGN-75 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial and remains in clinical development.